<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00059943</url>
  </required_header>
  <id_info>
    <org_study_id>01-136</org_study_id>
    <secondary_id>MSKCC-01136</secondary_id>
    <nct_id>NCT00059943</nct_id>
  </id_info>
  <brief_title>Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer</brief_title>
  <official_title>Pharmacokinetics of Weekly Docetaxel in Patients Age 65 and Older With Metastatic Breast or Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel, use different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well docetaxel works in treating older patients&#xD;
      with metastatic breast, lung, or prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the pharmacokinetics of docetaxel in older patients with metastatic breast,&#xD;
           lung, or prostate cancer.&#xD;
&#xD;
        -  Determine the response of patients treated with this drug.&#xD;
&#xD;
        -  Determine the toxicity of this drug in these patients.&#xD;
&#xD;
        -  Determine the short-term changes in functional status, in terms of activities of daily&#xD;
           living, independent activities of daily living, and Karnofsky performance status, in&#xD;
           patients treated with this drug.&#xD;
&#xD;
        -  Correlate the number of comorbid conditions at baseline with declines in functional&#xD;
           status in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: Patients receive docetaxel IV over 30 minutes once weekly for 3 weeks. Courses&#xD;
      repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of docetaxel</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between docetaxel clearance with estimated cytochrome p450 activity by the Erythromycin Breath Test</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between toxicity and functional status decline</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between comorbid conditions at baseline and declines in functional status</measure>
  </secondary_outcome>
  <condition>Breast Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven metastatic breast, lung, or prostate cancer&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No untreated CNS metastases&#xD;
&#xD;
          -  No symptomatic CNS metastases requiring escalating doses of corticosteroids&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  65 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 8.0 g/dL&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  SGOT and/or SGPT no greater than 2.5 times upper limit of normal (ULN) with alkaline&#xD;
             phosphatase no greater than ULN OR&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 4 times ULN with SGOT and SGPT no greater than&#xD;
             ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No history of cardiac arrhythmia&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior severe hypersensitivity reaction to docetaxel or other drugs containing&#xD;
             polysorbate 80&#xD;
&#xD;
          -  No allergy to macrolide antibiotics&#xD;
&#xD;
          -  No grade 2 or greater peripheral neuropathy&#xD;
&#xD;
          -  No concurrent serious or uncontrolled infection&#xD;
&#xD;
          -  Able to read, write, and converse in English&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent CYP3A4-inducing or inhibiting medications or herbal remedies&#xD;
&#xD;
          -  No concurrent grapefruit juice&#xD;
&#xD;
          -  No concurrent ethanol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arti Hurria, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>May 6, 2003</study_first_submitted>
  <study_first_submitted_qc>May 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2003</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

